Endonovo Therapeutics (ENDV) 10-Q 28 Dec 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Dec. 28, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-55453
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	0001528172
Entity Tax Identification Number	45-2552528
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6320 Canoga Avenue
Entity Address, Address Line Two	15th Floor
Entity Address, City or Town	Woodland Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91367
City Area Code	(800)
Local Phone Number	489-4774
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		318,751,597

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 0	$ 98
Prepaid expenses and other current assets	35,504	15,724
Total current assets	35,504	15,822
Patents, net	780,260	1,265,444
Total assets	815,764	1,281,266
Current liabilities
Accrued interest related to notes payable	4,417,039	3,542,650
Derivative liability	5,902,829	17,359,064
Total current liabilities	23,696,070	33,381,760
Acquisition payable	79,825	79,825
Total liabilities	23,775,895	33,461,585
COMMITMENTS AND CONTINGENCIES, note 9
Shareholders’ deficit
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 318,751,597 and 213,227,538 shares issued and outstanding as of September 30, 2023 and December 31, 2022	27,940	21,322
Additional paid-in capital	43,644,063	42,919,086
Stock subscriptions receivable	(1,570)	(1,570)
Accumulated deficit	(66,630,590)	(75,119,183)
Total shareholders’ deficit	(22,960,131)	(32,180,319)
Total liabilities and shareholders’ deficit	815,764	1,281,266
Super AA Super Voting Preferred Stock [Member]
Shareholders’ deficit
Series D convertible preferred stock, $0.0001 par value; 20,000 shares authorized, 0 and 50 issued and outstanding at September 30, 2023 and December 31, 2022	25	25
Series B Convertible Preferred Stock [Member]
Shareholders’ deficit
Series D convertible preferred stock, $0.0001 par value; 20,000 shares authorized, 0 and 50 issued and outstanding at September 30, 2023 and December 31, 2022	1	1
Series C Convertible Preferred Stock [Member]
Shareholders’ deficit
Series D convertible preferred stock, $0.0001 par value; 20,000 shares authorized, 0 and 50 issued and outstanding at September 30, 2023 and December 31, 2022
Series D Convertible Preferred Stock [Member]
Shareholders’ deficit
Series D convertible preferred stock, $0.0001 par value; 20,000 shares authorized, 0 and 50 issued and outstanding at September 30, 2023 and December 31, 2022
Nonrelated Party [Member]
Current liabilities
Accounts payable and accrued liabilities – related party	1,180,968	884,195
Deferred compensation – related party	4,229,029	3,918,788
Notes payable – former related party	6,952,372	7,041,145
Related Party [Member]
Current liabilities
Accounts payable and accrued liabilities – related party	278,665
Deferred compensation – related party	630,568	523,818
Notes payable – former related party	$ 104,600	$ 112,100

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Discounts on notes payable current	$ 28,210	$ 10,587
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	318,751,597	213,227,538
Common stock, shares outstanding	318,751,597	213,227,538
Super AA Super Voting Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	25,000	25,000
Preferred stock, shares outstanding	25,000	25,000
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000	50,000
Preferred stock, shares issued	600	600
Preferred stock, shares outstanding	600	600
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	8,000	8,000
Preferred stock, shares issued	738	738
Preferred stock, shares outstanding	738	738
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	0	50
Preferred stock, shares outstanding	0	50

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 1,520	$ 10,960	$ 134,260	$ 13,892
Cost of revenue	827	4,027	4,823	5,124
Gross profit	693	6,933	129,437	8,768
Operating expenses	473,490	503,711	2,262,833	2,790,057
Loss from operations	(472,797)	(496,778)	(2,133,396)	(2,781,289)
Other income (expense)
Change in fair value of derivative liability	0	(56,213)	11,445,466	(1,903,177)
Gain (loss) on settlement of debt	0	319,081	156,062	362,894
Other expense	(7,481)	(30,879)	(31,999)	(208,879)
Interest expense, net	(285,892)	(338,571)	(908,141)	(1,012,249)
Other income (expense)	(293,373)	(106,582)	10,661,388	(2,761,411)
Income (Loss) before income taxes	(766,170)	(603,360)	8,527,992	(5,542,700)
Provision for income taxes
Net Income (Loss)	$ (766,170)	$ (603,360)	$ 8,527,992	$ (5,542,700)
Basic Income (Loss) per share	$ (0.002)	$ 0	$ 0.03	$ (0.05)
Diluted Loss per share	$ 0	$ 0	$ 0	$ (0.05)
Weighted average common share outstanding:
Basic	298,391,943	153,599,760	276,355,156	122,537,266
Diluted	1,350,805,130	153,599,760	1,350,768,342	122,537,266

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities:
Net Income (Loss)	$ 8,527,992	$ (5,542,700)
Adjustments to reconcile net income (loss) to cash used in operating activities:
Amortization expense	485,185	485,184
Stock compensation expense	200,966
Fair value of equity issued for services	720,562	1,281,900
Loss (gain) on extinguishment of debt	(156,062)	(362,894)
Amortization of note discount and original issue discount	12,002	90,427
Change in fair value of derivative liability	(11,445,466)	1,903,177
Changes in assets and liabilities:
Prepaid expenses and other current assets	9,052	7,975
Account payable and accrued liabilities (related and unrelated parties)	49,534	297,250
Accrued interest	908,141	921,822
Deferred compensation	283,731	464,562
Net cash used in operating activities	(404,363)	(453,297)
Financing activities:
Proceeds from the issuance of notes payable	195,000	400,000
Repayments on former related party of notes payable	(7,500)	(9,500)
Repayments of convertible debt in cash	(40,000)
Proceeds from issuance of common stock and units, net	256,765
Net cash provided by financing activities	404,265	390,500
Net increase (decrease) in cash	(98)	(62,797)
Cash, beginning of year	98	85,936
Cash, end of period	0	23,139
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Non-Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	109,000	339,000
Conversion of Preferred C Stock to common stock	500
Issuance of common stock to settle debt	45,000
Debt discount from issuance of debt	32,875	44,098
Conversion of notes to common stock pursuant to settlement agreement	$ 159,419

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series AA Preferred Stock [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 25	$ 1			$ 7,449	$ 40,663,187	$ (1,570)	$ (56,443,416)	$ (15,774,324)
Balance, shares at Dec. 31, 2021	25,000	600	738	305	74,498,760
Shares issued for conversion of notes payable and accrued interest					$ 370	88,430			88,800
Shares issued for conversion of notes payable and accrued interest, shares					3,700,000
Common stock issued for settlement of debt					$ 243	45,904			46,147
Common stock issued for settlement of debt, shares					2,428,777
Net Income (loss)								(2,413,209)	(2,413,209)
Issuance of commitment shares in connection with promissory note					$ 70	15,680			15,750
Issuance of commitment shares in connection with promissory notes, shares					700,000
Balance at Mar. 31, 2022	$ 25	$ 1			$ 8,132	40,813,201	(1,570)	(58,856,625)	(18,036,836)
Balance, shares at Mar. 31, 2022	25,000	600	738	305	81,327,538
Balance at Dec. 31, 2021	$ 25	$ 1			$ 7,449	40,663,187	(1,570)	(56,443,416)	$ (15,774,324)
Balance, shares at Dec. 31, 2021	25,000	600	738	305	74,498,760
Shares issued for conversion of notes payable and accrued interest, shares									16,950,000
Common Shares issued for services									$ 1,281,900
Common Shares issued for services, shares									62,250,000
Net Income (loss)									$ (5,542,700)
Balance at Sep. 30, 2022	$ 25	$ 1			$ 15,922	42,365,859	(1,570)	(61,986,116)	(19,605,879)
Balance, shares at Sep. 30, 2022	25,000	600	738		159,227,538
Balance at Mar. 31, 2022	$ 25	$ 1			$ 8,132	40,813,201	(1,570)	(58,856,625)	(18,036,836)
Balance, shares at Mar. 31, 2022	25,000	600	738	305	81,327,538
Shares issued for conversion of notes payable and accrued interest					$ 650	114,550			115,200
Shares issued for conversion of notes payable and accrued interest, shares					6,500,000
Common Shares issued for services					$ 6,225	1,275,675			1,281,900
Common Shares issued for services, shares					62,250,000
Net Income (loss)								(2,526,131)	(2,526,131)
Issuance of commitment shares in connection with promissory note					$ 35	5,698			5,733
Issuance of commitment shares in connection with promissory notes, shares					350,000
Balance at Jun. 30, 2022	$ 25	$ 1			$ 15,042	42,209,124	(1,570)	(61,382,756)	(19,160,134)
Balance, shares at Jun. 30, 2022	25,000	600	738	305	150,427,538
Common Shares issued for services					$ 675	134,325			135,000
Common Shares issued for services, shares					6,750,000
Net Income (loss)								(603,360)	(603,360)
Issuance of commitment shares in connection with promissory note					$ 205	22,410			22,615
Issuance of commitment shares in connection with promissory notes, shares					2,050,000
Balance at Sep. 30, 2022	$ 25	$ 1			$ 15,922	42,365,859	(1,570)	(61,986,116)	(19,605,879)
Balance, shares at Sep. 30, 2022	25,000	600	738		159,227,538
Balance at Dec. 31, 2022	$ 25	$ 1			$ 21,322	42,919,086	(1,570)	(75,119,183)	(32,180,319)
Balance, shares at Dec. 31, 2022	25,000	600	738	50	213,227,538
Shares issued for conversion of notes payable and accrued interest					$ 1,090	107,910			109,000
Shares issued for conversion of notes payable and accrued interest, shares					10,900,000
Shares issued pursuant to make good provision					$ 151	24,719			24,870
Shares issued pursuant to make good provision, shares					1,507,277
Common stock issued for settlement of debt					$ 430	66,659			67,089
Common stock issued for settlement of debt, shares					4,300,590
Common Shares issued for services					$ 1,285	171,665			172,950
Common Shares issued for services, shares					12,850,000
Common stock issued for cash, net of fees					$ 2,250	204,750			207,000
Common stock issued for cash, net of fees, shares					22,500,000
Shares issued for conversion of Preferred Series D to common shares					$ 500	(500)
Shares issued for conversion of Preferred Series D to common shares, shares				(50)	5,000,000
Inducement loss related to conversion of preferred stock						39,398		(39,398)
Net Income (loss)								7,230,502	7,230,502
Balance at Mar. 31, 2023	$ 25	$ 1			$ 27,028	43,533,687	(1,570)	(67,928,079)	(24,368,908)
Balance, shares at Mar. 31, 2023	25,000	600	738		270,285,405
Balance at Dec. 31, 2022	$ 25	$ 1			$ 21,322	42,919,086	(1,570)	(75,119,183)	$ (32,180,319)
Balance, shares at Dec. 31, 2022	25,000	600	738	50	213,227,538
Shares issued for conversion of notes payable and accrued interest					$ 109,000
Shares issued for conversion of notes payable and accrued interest, shares					10,900,000				10,900,000
Shares issued pursuant to make good provision					$ 282,000
Shares issued pursuant to make good provision, shares					20,000,000
Common stock issued for settlement of debt, shares					4,300,590
Common Shares issued for services									$ 720,562
Common Shares issued for services, shares									43,800,000
Common stock issued for cash, net of fees, shares					5,967,590
Net Income (loss)									$ 8,527,992
Shares issued for conversion of deferred compensation					$ 24,338
Shares issued for conversion of deferred compensation, shares					1,667,000
Balance at Sep. 30, 2023	$ 25	$ 1			$ 27,940	43,644,063	(1,570)	(66,630,590)	(22,960,131)
Balance, shares at Sep. 30, 2023	25,000	600	738		289,152,405
Balance at Mar. 31, 2023	$ 25	$ 1			$ 27,028	43,533,687	(1,570)	(67,928,079)	(24,368,908)
Balance, shares at Mar. 31, 2023	25,000	600	738		270,285,405
Common Shares issued for services					$ 100	15,900			16,000
Common Shares issued for services, shares					1,000,000
Common stock issued for cash, net of fees					$ 500	45,500			46,000
Common stock issued for cash, net of fees, shares					5,000,000
Net Income (loss)								2,063,660	2,063,660
Shares issued for conversion of deferred compensation					$ 167	24,171			24,338
Shares issued for conversion of deferred compensation, shares					1,667,000
Issuance of commitment shares in connection with promissory note					$ 85	11,040			11,125
Issuance of commitment shares in connection with promissory notes, shares					850,000
Stock-based compensation						6,025			6,025
Balance at Jun. 30, 2023	$ 25	$ 1			$ 27,940	43,644,063	(1,570)	(66,082,348)	(22,411,889)
Balance, shares at Jun. 30, 2023	25,000	600	738		289,152,405
Common Shares issued for services
Common Shares issued for services, shares					8,000,000
Common stock issued for cash, net of fees
Common stock issued for cash, net of fees, shares									1,000,000
Net Income (loss)								(766,170)	$ (766,170)
Shares issued for conversion of deferred compensation
Issuance of commitment shares in connection with promissory note					$ 25	3,225			3,250
Issuance of commitment shares in connection with promissory notes, shares					2,000,000
Stock-based compensation					$ 35	4,515			4,550
Stock issued during period, shares, employee benefit plan					350,000
Balance at Sep. 30, 2023	$ 25	$ 1			$ 27,940	$ 43,644,063	$ (1,570)	$ (66,630,590)	$ (22,960,131)
Balance, shares at Sep. 30, 2023	25,000	600	738		289,152,405

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV). The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders). The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke. Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical ® ® bioelectricity The Company intends to be structured into two separate divisions: ■ A commercial stage developer primarily of non-invasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness, and wound curatives with many of its products marketed under the SofPulse® brand name. This division will be controlled by Ira Weisberg, the Company’s President and Chief Commercial Officer. ■ M&A division with a strategy of purchasing profitable companies, which will be managed by the Company’s current Chief Executive Officer.

Summary of significant accounti

Summary of significant accounting policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of significant accounting policies	Note 2 – Summary of significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed balance sheet as of September 30, 2023, the consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022, the consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three and nine months ended September 30, 2023 and 2022 are unaudited; however, in the opinion of management such interim consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable. As of September 30, 2023, the Company had cash of approximately $ 0 23.1 0.4 66.6 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) During the nine months ended September 30, 2023, the Company has raised $ 0.5 On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $ 25.2 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the nine months ended September 30, 2023, include stock options, warrants, and notes payable. The Company has 6,011,750 263,070 2,000 The components of basic and diluted income (loss) per share for the nine months ended September 30, 2023 and 2022 were as follows: Schedule of Earnings Per Share Basic and Diluted 2023 2022 Nine months ended September 30, 2023 2022 Numerator: Net income (loss) attributable to common shareholders $ 8,857,992 $ (5,542,700 ) Effect of dilutive securities Convertible notes (10,823,217 ) - Net loss for diluted earnings per share $ (2,295,225 ) $ (5,542,700 ) Denominator: Weighted-average number of common shares outstanding during the period 276,355,156 55,303,026 Dilutive effect of convertible notes payable 1,074,413,187 - Common stock and common stock equivalents used for diluted loss per share 1,350,768,342 55,303,026 The components of basic and diluted income (loss) per share for the three months ended September 30, 2023 and 2022 were as follows: 2023 2022 Three months ended September 30, 2023 2022 Numerator: Net income (loss) attributable to common shareholders $ (766,170 ) $ (603,360 ) Effect of dilutive securities Convertible notes 285,892 - Net loss for diluted earnings per share $ (480,278 ) $ (603,360 ) Denominator: Weighted-average number of common shares outstanding during the period 298,391,943 153,599,760 Dilutive effect of convertible notes payable 1,074,413,187 - Common stock and common stock equivalents used for diluted loss per share 1,372,805,130 153,599,760 Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Newly Adopted Accounting Principles The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s consolidated financial statements.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3 - Revenue Recognition Contracts with Customers The Company adopted ASC 606, Revenue from Contracts with Customers . The Company routinely plans on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, the Company has an unconditional right to receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped. In connection with offering products and services provided to the end user by third-party vendors, the Company reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, the Company considers whether the Company acts as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Sources of Revenue The Company has identified the following revenues by revenue source: 1. Sales to plastic surgeons 2. Sales to wound care facilities 3. Sales to hospital 4. Sales to other physicians 5. Royalty fee from licensing, net For the three and nine months ended September 30, 2023 and 2022, the sources of revenue were as follows: Schedule of Source of Revenue 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended 2023 2022 2023 2022 Royalty/licensing, net $ - $ - $ 126,520 $ - Direct sales- medical care providers, gross 1,520 10,960 7,740 13,892 Total sources of revenue $ 1,520 $ 10,960 $ 134,260 $ 13,892 The royalty/licensing revenue recognized in the nine months ended September 30, 2023, resulted from specific transactions. No general patent rights were assigned to the distributor. The royalty / licensing revenue is recorded on a net basis as the Company was not considered the principal but an agent for accounting purposes. The royalty / licensing revenue, net includes an ongoing contract with a customer that has a total gross sales value of $ 300,000 126,520 1,000 On January 25, 2023, the Company entered into a sales support services agreement with Pulse Therapeutic Technology (“PTT”), an entity controlled by a former related party, under which PTT has been selling SofPulse® on a nonexclusive basis. Pursuant to such agreement, the deferred compensation owed to this former related party has been fully extinguished for a total amount of approximately $ 118,000 Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Practical Expedients Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Patents

Patents	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 4 – Patents In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $ 4,500,000 2024 Schedule of Patents September 30, 2023 December 31, 2022 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 3,719,740 3,234,556 Patents, net $ 780,260 $ 1,265,444 Amortization expense associated with patents was $ 485,184 The estimated future amortization expense related to patents as of September 30, 2023, is as follows: Schedule of Estimated Future Amortization Expense Twelve Months Ending September 30, Amount 2024 $ 646,192 2025 134,068 Total $ 780,260

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Notes Payable	Note 5- Notes Payable As of September 30, 2023, and December 31, 2022, the notes payable activity was as follows: Schedule of Notes Payable September 30, 2023 December 31, 2022 Notes payable at beginning of period $ 7,163,832 $ 7,256,930 Notes payable issued 195,000 465,000 Repayments of notes payable in cash (40,000 ) (14,000 ) Settlement on note payable (133,650 ) (163,826 ) Less amounts converted to stock (100,000 ) (380,272 ) Notes payable at end of period 7,085,182 7,163,832 Less debt discount (28,210 ) (10,587 ) Note payable, net $ 7,056,972 $ 7,153,245 Notes payable issued to a former related party $ 104,600 $ 112,100 Notes payable issued to non-related parties $ 6,952,372 $ 7,041,145 The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former Non-related Total Past due $ 104,600 $ 6,770,582 $ 6,875,182 September 30, 2024 - 210,000 210,000 $ 104,600 $ 6,948,082 $ 7,085,182 Activity for the nine months ended September 30, 2023 Fixed rate notes During the nine months ended September 30, 2023, the Company converted $ 100,000 9,000 10,900,000 During the nine months ended September 30, 2023, the Company executed an amendment or allonges to three fixed rate notes to extend the maturity date in exchange for $ 20,000 1,000,000 2,500 During the nine months ended September 30, 2023, the Company issued five fixed-rate notes for an aggregate amount of $ 195,000 10 15 1 9 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) As of September 30, 2023, the Company has a total of twenty-four (24) fixed-rate notes, of which eighteen (18) have a make good provision for a total principal of $ 1,440,000 338,403 1,849,728 1,819,728 429,500 310,960 Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares. 250,000 certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium. Variable-rate notes During the nine months ended September 30, 2023, the Company executed a settlement agreement with one investor to extinguish the remaining principal balance of a promissory note into 4,300,590 77,000 Fixed Rate note (former related party) Notes payable to a former related party in the aggregate amount of $ 104,600 10 12 7,500 Activity for the nine months ended September 30, 2022 Fixed rates Notes During the nine months ended September 30, 2022, the Company issued five (5) fixed rate promissory notes totaling $ 400,000 400,000 15 18 As of September 30, 2022, the Company has eighteen (18) fixed-rate promissory notes with an outstanding balance of $ 1,920,900 1,045,900 1,400,000 Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares. 209,000 During the nine months ended September 30, 2022, the Company converted $ 124,900 214,100 16,950,000 Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company. 243,000 Variable-rate notes The gross amount of all convertible notes with variable conversion rates outstanding as of September 30, 2022, is $ 4,607,100 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Shareholders_ Deficit

Shareholders’ Deficit	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Shareholders’ Deficit	Note 6 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 Schedule of Preferred Stock Number of Shares Number of Shares Par Value Liquidation Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 - $ 0.0001 $ 1,000 Undesignated 3,922,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million ( 1,000,000 0.001 Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. There was no activity during the nine months ended September 30, 2023. There were 25,000 Series B Convertible Preferred Stock On February 7, 2017, the Company filed a certificate of designation for 50,000 75 three-year 150 100 There was no activity during the nine months ended September 30, 2023. There were 600 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Series C Convertible Redeemable Preferred Stock On December 22, 2017, the Company filed a certificate of designation for 8,000 20 1,000 the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $ 1,000 There was no activity during the nine months ended September 30, 2023. There were 738 Series D Convertible Preferred Stock On November 11, 2019, the Company filed a certificate of designation for 20,000 0.01 The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $ 1,000 During the six months ended June 30, 2023, the Company issued 5,000,000 50 The Company is also committed to providing additional shares of common stock if the holders of Series D do not realize a 15% profit on the resale of the conversion shares. 0 50 Common Stock Activity during the nine months ended September 30, 2023 During the nine months ended September 30, 2023, the Company issued 10,900,000 109,000 During the nine months ended September 30, 2023, the Company issued 1,507,277 24,870 During the nine months ended September 30, 2023, the Company issued 4,300,590 113,650 77,000 During the nine months ended September 30, 2023, the Company issued 1,667,000 24,338 During the nine months ended September 30, 2023, the Company issued 5,967,590 During the nine months ended September 30, 2023, the Company issued 43,800,000 720,562 During the nine months ended September 30, 2023, the Company issued 5,000,000 50 39,398 During the nine months ended September 30, 2023, the Company issued 5 1/2 units or the equivalent of 27,500,000 253,000 During the nine months ended September 30, 2023, the Company issued 1,850,000 25,625 During the nine months ended September 30, 2023, the Company issued 1,000,000 11,125 Activity during the nine months ended September 30, 2022 During the nine months ended September 30, 2022, the Company issued 16,950,000 214,100 124,900 During the nine months ended September 30, 2022, the Company issued 2,428,777 During the nine months ended September 30, 2022, the Company issued 3,100,000 During the nine months ended September 30, 2022, the Company issued 62,250,000 1,281,900 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Stock Options The balance of all stock options outstanding as of September 30, 2023, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at December 31, 2022 3,012,410 $ 0.22 3.40 31,200 Granted 3,000,000 $ 0.01 - Cancelled (660 ) $ 11.60 - Exercised - $ - - Outstanding at September 30, 2023 6,011,750 $ 0.12 3.06 $ - Exercisable at September 30, 2023 1,011,750 $ 0.64 1.83 $ - Share-based compensation expenses for the nine months ended September 30, 2023 and 2022, totaled approximately $ 6,000 0 36,000 2.5 Warrants The balance of all warrants outstanding as of September 30, 2023, is as follows: Schedule of Warrants Outstanding Outstanding Warrants Weighted Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at December 31, 2022 2,000 $ 50.0 0.22 Granted - $ - - Cancelled (2,000 ) $ 50.0 - Exercised - $ - Outstanding at September 30, 2023 - $ - - Exercisable at September 30, 2023 - $ - - Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Related Party and former relate

Related Party and former related parties Transactions.	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party and former related parties Transactions.	Note 7 – Related Party and former related parties Transactions. One executive officer of the Company has agreed to defer a portion of his compensation until cash flow improves. As of September 30, 2023, the balance of the deferred compensation was $ 630,568 225,000 118,250 As of September 30, 2023, the Company issued for the issuance of 20,000,000 282,000 One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of September 30, 2023, the balance of his deferred compensation was $ 632,257 From time-to-time officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at September 30, 2023, was $ 5,340 5,215 2,500 As of September 30, 2023, notes payable remained outstanding to the former President of the Company, in the amount of $ 104,600 88,045

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8 – Fair Value Measurements The Company issued Variable Debentures, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Schedule of Conversion Feature Using Black Scholes Option Pricing Model Nine months ended September 30, 2023 2022 Expected term 1 month 1 month Exercise price $ 0.0066 0.0151 $ 0.004 0.015 Expected volatility 154 158 % 152 169 % Expected dividends None None Risk-free interest rate 4.64 5.40 % 1.63 2.80 % Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net income (loss) is therefore subject to significant fluctuation and will continue to be so until the Company’s variable debentures, which the convertible feature is associated with, are converted into common stock or paid in full in cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. Company will perform valuation of derivative liabilities as a part of its 2023 10-K filing. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2023: Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2022 $ 17,359,064 Settlement debt (10,769 ) Change in estimated fair value (11,445,466 ) Balance September 30, 2023 $ 5,902,829 Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of September 30, 2023: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Active Significant Other Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total As of September 30, 2023 Derivative liability $ - $ - $ 5,902,829 $ 5,902,829 Total $ - $ - $ 5,902,829 $ 5,902,829 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Legal Matters The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of September 30, 2023, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2023
Risks and Uncertainties [Abstract]
Concentrations	Note 10 – Concentrations Sales During the nine months ended September 30, 2023, we had one significant customer, which accounted for approximately 100 Supplier We also have a single source for our bioelectric medical devices, which account for 100

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 11 – Subsequent Events Management has evaluated events that have occurred subsequent to the date of these consolidated condensed financial statements and has determined that no such reportable subsequent events exist through the date the financial statements were issued in accordance with FASB ASC Topic 855, “Subsequent Events.”

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed balance sheet as of September 30, 2023, the consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022, the consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three and nine months ended September 30, 2023 and 2022 are unaudited; however, in the opinion of management such interim consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.
Liquidity and Going Concern	Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable. As of September 30, 2023, the Company had cash of approximately $ 0 23.1 0.4 66.6 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) During the nine months ended September 30, 2023, the Company has raised $ 0.5 On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $ 25.2 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the nine months ended September 30, 2023, include stock options, warrants, and notes payable. The Company has 6,011,750 263,070 2,000 The components of basic and diluted income (loss) per share for the nine months ended September 30, 2023 and 2022 were as follows: Schedule of Earnings Per Share Basic and Diluted 2023 2022 Nine months ended September 30, 2023 2022 Numerator: Net income (loss) attributable to common shareholders $ 8,857,992 $ (5,542,700 ) Effect of dilutive securities Convertible notes (10,823,217 ) - Net loss for diluted earnings per share $ (2,295,225 ) $ (5,542,700 ) Denominator: Weighted-average number of common shares outstanding during the period 276,355,156 55,303,026 Dilutive effect of convertible notes payable 1,074,413,187 - Common stock and common stock equivalents used for diluted loss per share 1,350,768,342 55,303,026 The components of basic and diluted income (loss) per share for the three months ended September 30, 2023 and 2022 were as follows: 2023 2022 Three months ended September 30, 2023 2022 Numerator: Net income (loss) attributable to common shareholders $ (766,170 ) $ (603,360 ) Effect of dilutive securities Convertible notes 285,892 - Net loss for diluted earnings per share $ (480,278 ) $ (603,360 ) Denominator: Weighted-average number of common shares outstanding during the period 298,391,943 153,599,760 Dilutive effect of convertible notes payable 1,074,413,187 - Common stock and common stock equivalents used for diluted loss per share 1,372,805,130 153,599,760
Accounts Receivable	Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)
Newly Adopted Accounting Principles	Newly Adopted Accounting Principles The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s consolidated financial statements.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Earnings Per Share Basic and Diluted	The components of basic and diluted income (loss) per share for the nine months ended September 30, 2023 and 2022 were as follows: Schedule of Earnings Per Share Basic and Diluted 2023 2022 Nine months ended September 30, 2023 2022 Numerator: Net income (loss) attributable to common shareholders $ 8,857,992 $ (5,542,700 ) Effect of dilutive securities Convertible notes (10,823,217 ) - Net loss for diluted earnings per share $ (2,295,225 ) $ (5,542,700 ) Denominator: Weighted-average number of common shares outstanding during the period 276,355,156 55,303,026 Dilutive effect of convertible notes payable 1,074,413,187 - Common stock and common stock equivalents used for diluted loss per share 1,350,768,342 55,303,026 The components of basic and diluted income (loss) per share for the three months ended September 30, 2023 and 2022 were as follows: 2023 2022 Three months ended September 30, 2023 2022 Numerator: Net income (loss) attributable to common shareholders $ (766,170 ) $ (603,360 ) Effect of dilutive securities Convertible notes 285,892 - Net loss for diluted earnings per share $ (480,278 ) $ (603,360 ) Denominator: Weighted-average number of common shares outstanding during the period 298,391,943 153,599,760 Dilutive effect of convertible notes payable 1,074,413,187 - Common stock and common stock equivalents used for diluted loss per share 1,372,805,130 153,599,760

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Source of Revenue	For the three and nine months ended September 30, 2023 and 2022, the sources of revenue were as follows: Schedule of Source of Revenue 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended 2023 2022 2023 2022 Royalty/licensing, net $ - $ - $ 126,520 $ - Direct sales- medical care providers, gross 1,520 10,960 7,740 13,892 Total sources of revenue $ 1,520 $ 10,960 $ 134,260 $ 13,892

Patents (Tables)

Patents (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents	Schedule of Patents September 30, 2023 December 31, 2022 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 3,719,740 3,234,556 Patents, net $ 780,260 $ 1,265,444
Schedule of Estimated Future Amortization Expense	The estimated future amortization expense related to patents as of September 30, 2023, is as follows: Schedule of Estimated Future Amortization Expense Twelve Months Ending September 30, Amount 2024 $ 646,192 2025 134,068 Total $ 780,260

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Notes Payable	As of September 30, 2023, and December 31, 2022, the notes payable activity was as follows: Schedule of Notes Payable September 30, 2023 December 31, 2022 Notes payable at beginning of period $ 7,163,832 $ 7,256,930 Notes payable issued 195,000 465,000 Repayments of notes payable in cash (40,000 ) (14,000 ) Settlement on note payable (133,650 ) (163,826 ) Less amounts converted to stock (100,000 ) (380,272 ) Notes payable at end of period 7,085,182 7,163,832 Less debt discount (28,210 ) (10,587 ) Note payable, net $ 7,056,972 $ 7,153,245 Notes payable issued to a former related party $ 104,600 $ 112,100 Notes payable issued to non-related parties $ 6,952,372 $ 7,041,145
Schedule of Maturity Dates of Notes Payable	The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former Non-related Total Past due $ 104,600 $ 6,770,582 $ 6,875,182 September 30, 2024 - 210,000 210,000 $ 104,600 $ 6,948,082 $ 7,085,182

Shareholders_ Deficit (Tables)

Shareholders’ Deficit (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Preferred Stock	The Company has authorized 5,000,000 Schedule of Preferred Stock Number of Shares Number of Shares Par Value Liquidation Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 - $ 0.0001 $ 1,000 Undesignated 3,922,000 - - -
Schedule of Stock Options Outstanding	The balance of all stock options outstanding as of September 30, 2023, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at December 31, 2022 3,012,410 $ 0.22 3.40 31,200 Granted 3,000,000 $ 0.01 - Cancelled (660 ) $ 11.60 - Exercised - $ - - Outstanding at September 30, 2023 6,011,750 $ 0.12 3.06 $ - Exercisable at September 30, 2023 1,011,750 $ 0.64 1.83 $ -
Schedule of Warrants Outstanding	The balance of all warrants outstanding as of September 30, 2023, is as follows: Schedule of Warrants Outstanding Outstanding Warrants Weighted Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at December 31, 2022 2,000 $ 50.0 0.22 Granted - $ - - Cancelled (2,000 ) $ 50.0 - Exercised - $ - Outstanding at September 30, 2023 - $ - - Exercisable at September 30, 2023 - $ - -

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Conversion Feature Using Black Scholes Option Pricing Model	Schedule of Conversion Feature Using Black Scholes Option Pricing Model Nine months ended September 30, 2023 2022 Expected term 1 month 1 month Exercise price $ 0.0066 0.0151 $ 0.004 0.015 Expected volatility 154 158 % 152 169 % Expected dividends None None Risk-free interest rate 4.64 5.40 % 1.63 2.80 % Forfeitures None None
Schedule of Fair Value of Derivative Liability	The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2023: Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2022 $ 17,359,064 Settlement debt (10,769 ) Change in estimated fair value (11,445,466 ) Balance September 30, 2023 $ 5,902,829
Schedule of Liabilities Significant Unobservable Inputs	The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of September 30, 2023: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Active Significant Other Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total As of September 30, 2023 Derivative liability $ - $ - $ 5,902,829 $ 5,902,829 Total $ - $ - $ 5,902,829 $ 5,902,829

Schedule of Earnings Per Share

Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Accounting Policies [Abstract]
Net income (loss) attributable to common shareholders	$ (766,170)	$ (603,360)	$ 8,857,992	$ (5,542,700)
Convertible notes	285,892		(10,823,217)
Net loss for diluted earnings per share	$ (480,278)	$ (603,360)	$ (2,295,225)	$ (5,542,700)
Weighted-average number of common shares outstanding during the period	298,391,943	153,599,760	276,355,156	55,303,026
Dilutive effect of convertible notes payable	1,074,413,187		1,074,413,187
Common stock and common stock equivalents used for diluted loss per share	1,372,805,130	153,599,760	1,350,768,342	55,303,026

Summary of significant accoun_4

Summary of significant accounting policies (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Sep. 26, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash		$ 0		$ 0
Working capital		23,100,000		23,100,000
Net cash provided by (used in) operating activities				404,363	$ 453,297
Accumulated deficit		$ 66,630,590		66,630,590		$ 75,119,183
Proceeds from equity financing				$ 500,000
Anti dilutive shares		1,074,413,187		1,074,413,187
Accounts receivable allowance for credit loss, current		$ 0		$ 0		$ 0
Share-Based Payment Arrangement, Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Anti dilutive shares				6,011,750	263,070
Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Anti dilutive shares					2,000
Assets Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase of assets and Liabilities	$ 25,200,000

Schedule of Source of Revenue (

Schedule of Source of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 1,520	$ 10,960	$ 134,260	$ 13,892
Royalty/Licensing, Net [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue			126,520
Direct Sales Medical Care Providers Gross [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 1,520	$ 10,960	$ 7,740	$ 13,892

Revenue Recognition (Details Na

Revenue Recognition (Details Narrative)	9 Months Ended
	Sep. 30, 2023 USD ($) Integer	Jan. 25, 2023 USD ($)
Sales Support Service Agreement [Member] | Pulse Therapeutic Technology [Member]
Disaggregation of Revenue [Line Items]
Deferred compensation		$ 118,000
Royalty/Licensing, Net [Member]
Disaggregation of Revenue [Line Items]
Gross sale value of ongoing contract	$ 300,000
Contract with Customer, Liability, Revenue Recognized	$ 126,520
Number of Reporting Units | Integer	1,000

Schedule of Patents (Details)

Schedule of Patents (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000	$ 4,500,000
Less accumulated amortization	3,719,740	3,234,556
Patents, net	$ 780,260	$ 1,265,444

Schedule of Estimated Future Am

Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 646,192
2025	134,068
Patents, net	$ 780,260	$ 1,265,444

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Dec. 31, 2017	Sep. 30, 2023
Amortization expense		$ 485,184
Rio Grande Neurosciences, Inc. [Member]
Acquisition of patents	$ 4,500,000
Patents expiration period	2024

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Notes payable at beginning of period	$ 7,163,832	$ 7,256,930
Notes payable issued	195,000	465,000
Repayments of notes payable in cash	(40,000)	(14,000)
Settlement on note payable	(133,650)	(163,826)
Less amounts converted to stock	(100,000)	(380,272)
Notes payable at end of period	7,085,182	7,163,832
Less debt discount	(28,210)	(10,587)
Note payable, net	7,056,972	7,153,245
Former Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable	104,600	112,100
Nonrelated Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable	$ 6,952,372	$ 7,041,145

Schedule of Maturity Dates of N

Schedule of Maturity Dates of Notes Payable (Details)	Sep. 30, 2023 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Past due	$ 6,875,182
June 30, 2024	210,000
Total	7,085,182
Former Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Past due	104,600
June 30, 2024
Total	104,600
Nonrelated Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Past due	6,770,582
June 30, 2024	210,000
Total	$ 6,948,082

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt conversion, stock issued value			$ 100,000	$ 214,100
Debt instrument, accrued interest			$ 9,000
Debt conversion, stock issued shares			10,900,000	16,950,000
Principal payment of debt			$ 20,000
Number of shares issued	1,000,000
Extension fee payable			2,500
Note payable issued			195,000		$ 465,000
Principal amount	$ 1,440,000		1,440,000
Accrued interest	338,403	$ 124,900	338,403	$ 124,900
Notes payable	7,085,182		$ 7,085,182		7,163,832	$ 7,256,930
Debt instrument description			the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares.
Value of good provision	250,000		$ 250,000
Description of percentage of cash premium			certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium.	Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company.
Gain on debt extinguishment	0	319,081	$ 156,062	$ 362,894
Proceeds from notes payable			195,000	400,000
Prepayment penalty		243,000		243,000
Former Related Party [Member]
Debt Instrument [Line Items]
Principal payment of debt			7,500
Note payable	104,600		104,600		112,100
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Notes payable	1,849,728		1,849,728		1,819,728
Accrued interest	$ 429,500		$ 429,500		$ 310,960
Variable Rate Notes [Member]
Debt Instrument [Line Items]
Debt conversion, stock issued shares			4,300,590
Gain on debt extinguishment			$ 77,000
Convertible notes		4,607,100		4,607,100
Five Fixed Rated Notes [Member]
Debt Instrument [Line Items]
Promissory notes		400,000		400,000
Proceeds from notes payable				400,000
Eighteen Fixed Rated Notes [Member]
Debt Instrument [Line Items]
Notes payable		1,920,900		1,920,900
Eighteen Fixed Rated Notes [Member] | Past Maturity [Member]
Debt Instrument [Line Items]
Notes payable		1,045,900		1,045,900
Fourteen Fixed Rated Notes [Member]
Debt Instrument [Line Items]
Principal amount		1,400,000		1,400,000
Value of good provision		$ 209,000		$ 209,000
Debt instrument description				Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares.
Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	10%		10%
Maturity term			1 month
Minimum [Member] | Former Related Party [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	10%		10%
Minimum [Member] | Five Fixed Rated Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate		15%		15%
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	15%		15%
Maturity term			9 months
Maximum [Member] | Former Related Party [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	12%		12%
Maximum [Member] | One Promissory Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate		18%		18%

Schedule of Preferred Stock (De

Schedule of Preferred Stock (Details)	Sep. 30, 2023 USD ($) $ / shares shares
Series AA [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	1,000,000
Number of Shares Outstanding	25,000
Par Value | $ / shares	$ 0.0010
Liquidation Value | $
Preferred Series B [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	50,000
Number of Shares Outstanding	600
Par Value | $ / shares	$ 0.0001
Liquidation Value | $	$ 100
Preferred Series C [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	8,000
Number of Shares Outstanding	738
Par Value | $ / shares	$ 0.0001
Liquidation Value | $	$ 1,000
Preferred Series D [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	20,000
Number of Shares Outstanding
Par Value | $ / shares	$ 0.0001
Liquidation Value | $	$ 1,000
Undesignated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	3,922,000
Number of Shares Outstanding
Par Value | $ / shares
Liquidation Value | $

Schedule of Stock Options Outst

Schedule of Stock Options Outstanding (Details) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Stock Options Outstanding, Beginning Balance | shares	3,012,410
Weighted Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 0.22
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	3 years 4 months 24 days
Aggregated Intrinsic Value, Outstanding Beginning Balance | $	$ 31,200
Stock Options Outstanding, Granted | shares	3,000,000
Weighted Average Exercise Price Per Share, Granted | $ / shares	$ 0.01
Stock Options Outstanding, Cancelled | shares	(660)
Weighted Average Exercise Price Per Share, Cancelled | $ / shares	$ 11.60
Stock Options Outstanding, Exercised | shares
Weighted Average Exercise Price Per Share, Exercised | $ / shares
Stock Options Outstanding, Ending Balance | shares	6,011,750
Weighted Average Exercise Price Per Share, Ending Balance | $ / shares	$ 0.12
Weighted Average Remaining Contractual Term (years), Ending	3 years 21 days
Aggregated Intrinsic Value, Ending | $
Stock Options Outstanding, Exercisable Ending Balance | shares	1,011,750
Weighted Average Exercise Price Per Share, Exercisable Ending Balance | $ / shares	$ 0.64
Weighted Average Remaining Contractual Term (years), Exercisable	1 year 9 months 29 days
Aggregated Intrinsic Value, Exercisable Ending | $

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares Outstanding, Beginning Balance | shares	2,000
Weighted Average Exercise Price Per Share, Outstanding Beginning Balance | $ / shares	$ 50
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	2 months 19 days
Shares, Granted | shares
Weighted Average Exercise Price Per Share, Granted | $ / shares
Shares, Cancelled | shares	(2,000)
Weighted Average Exercise Price Per Share, Cancelled | $ / shares	$ 50
Shares, Exercised | shares
Weighted Average Exercise Price Per Share, Exercised | $ / shares
Shares Outstanding, Ending Balance | shares
Weighted Average Exercise Price Per Share, Outstanding Ending Balance | $ / shares
Shares Exercisable, Ending Balance | shares
Weighted Average Exercise Price Per Share, Exercisable Ending Balance | $ / shares

Shareholders_ Deficit (Details

Shareholders’ Deficit (Details Narrative) - USD ($)					3 Months Ended						6 Months Ended	9 Months Ended
	Jan. 29, 2020	Dec. 22, 2017	Feb. 07, 2017	Feb. 22, 2013	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Nov. 11, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued for conversion of notes payable, shares												10,900,000	16,950,000
Conversion of common stock							$ 109,000		$ 115,200	$ 88,800
Issuance of common stock					1,000,000
Gain on debt extinguishment					$ 0			$ 319,081				$ 156,062	$ 362,894
Principal amount					1,440,000							$ 1,440,000
Fair value of defered compensation						$ 24,338
Shares issued for common stock for services, shares												43,800,000	62,250,000
Shares issued for common stock for services, value						16,000	172,950	135,000	$ 1,281,900			$ 720,562	$ 1,281,900
Common stock new issuance, value						$ 46,000	$ 207,000
Accrued interest					338,403			$ 124,900				338,403	124,900
Share-based compensation expenses												6,000	$ 0
Unrecognized stock-based compensation expense					$ 36,000							$ 36,000
Remaining vesting period												2 years 6 months
Securities Purchase Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock												1,850,000
Shares issued for common stock for services, value												$ 25,625
Securities Purchase Agreements One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock												1,000,000
Shares issued for common stock for services, value												$ 11,125
Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock													3,100,000
Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock												27,500,000
Common stock new issuance, value												$ 253,000
One Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock												1,507,277	2,428,777
Gain on debt extinguishment												$ 24,870
Series AA Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized				1,000,000
Preferred stock, par value				$ 0.001
Preferred stock voting rights				Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.
Preferred stock, shares outstanding					25,000							25,000		25,000
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized			50,000
Preferred stock, shares outstanding					600							600		600
Stated value dividend			75%
Warrants term			three-year
Share exercise price			150%
Liquidation value of preferred stock, per share			$ 100
Series C Convertible Redeemable Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized		8,000
Preferred stock, shares outstanding					738							738		738
Liquidation value of preferred stock, per share		$ 1,000			$ 1,000							$ 1,000
Preferred stock, dividend per share		$ 20
Change in rights due to amendment and restated certificate, description	the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock.
Series D Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized					20,000							20,000		20,000	20,000
Preferred stock, par value					$ 0.0001							$ 0.0001		$ 0.0001
Preferred stock, shares outstanding					0	0					0	0		50
Liquidation value of preferred stock, per share					$ 1,000							$ 1,000
Conversion price															0.01%
Number of shares issued						5,000,000					5,000,000
Shares issued for conversion of notes payable, shares											50
Conversion of stock description											The Company is also committed to providing additional shares of common stock if the holders of Series D do not realize a 15% profit on the resale of the conversion shares.
Series D Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Inducement loss												$ 39,398
Preferred Stock Designated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized					5,000,000							5,000,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued					5,000,000							5,000,000
Shares issued for conversion of notes payable, shares													16,950,000
Shares issued for conversion of notes payable, shares							10,900,000		6,500,000	3,700,000		10,900,000
Conversion of common stock							$ 1,090		$ 650	$ 370		$ 109,000
Issuance of common stock						5,000,000	22,500,000					5,967,590
Gain on debt extinguishment												$ 77,000
Debt conversion, stock issued shares							4,300,590			2,428,777		4,300,590
Principal amount					$ 113,650							$ 113,650
Number of shares issued, share						1,667,000						1,667,000
Fair value of defered compensation						$ 167						$ 24,338
Shares issued for common stock for services, shares					8,000,000	1,000,000	12,850,000	6,750,000	62,250,000
Shares issued for common stock for services, value						$ 100	$ 1,285	$ 675	$ 6,225
Common stock new issuance, value						$ 500	$ 2,250
Shares issued for conversion of notes payable													$ 214,100
Accrued interest								$ 124,900					$ 124,900
Common Stock [Member] | Series D Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued for conversion of notes payable, shares												50

Related Party and former rela_2

Related Party and former related parties Transactions. (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Related Party Transaction [Line Items]
Number of shares issued, value	$ 24,870
Repayment of debt		$ 7,500	$ 9,500
Officer [Member]
Related Party Transaction [Line Items]
Due to officer		$ 5,340
Common Stock [Member]
Related Party Transaction [Line Items]
Number of shares issued	1,507,277	20,000,000
Number of shares issued, value	$ 151	$ 282,000
Executive Officer [Member]
Related Party Transaction [Line Items]
Deferred compensation		630,568
Accrual deferred compensation		225,000
Cash repayments of deferred compensation		118,250
Advance from officer		5,215
Repayment of debt		2,500
One Former Executive Officer [Member]
Related Party Transaction [Line Items]
Deferred compensation		632,257
Former President [Member]
Related Party Transaction [Line Items]
Notes payable – former related party		104,600
Interest payable		$ 88,045

Schedule of Conversion Feature

Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares	Sep. 30, 2022 $ / shares
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	1 month	1 month
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.0066	0.004
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.0151	0.015
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	154	152
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	158	169
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0	0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	4.64	1.63
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	5.40	2.80
Forfeitures [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0	0

Schedule of Fair Value of Deriv

Schedule of Fair Value of Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member]	9 Months Ended
	Sep. 30, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, beginning balance	$ 17,359,064
Settlement debt	(10,769)
Change in estimated fair value	(11,445,466)
Derivative Liability, ending balance	$ 5,902,829

Schedule of Liabilities Signifi

Schedule of Liabilities Significant Unobservable Inputs (Details)	Sep. 30, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 5,902,829
Total	5,902,829
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	5,902,829
Total	$ 5,902,829

Concentrations (Details Narrati

Concentrations (Details Narrative) - Revenue Benchmark [Member]	9 Months Ended
	Sep. 30, 2023
Customer Concentration Risk [Member] | One Significant Customer [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	100%
Supplier Concentration Risk [Member] | Supplier [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	100%